annual CFO:
-$347.69M+$10.30M(+2.88%)Summary
- As of today (June 28, 2025), DNLI annual cash flow from operations is -$347.69 million, with the most recent change of +$10.30 million (+2.88%) on December 31, 2024.
- During the last 3 years, DNLI annual CFO has fallen by -$136.31 million (-64.48%).
- DNLI annual CFO is now -183.55% below its all-time high of $416.15 million, reached on December 31, 2020.
Performance
DNLI Cash from operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFO:
-$131.47M-$47.75M(-57.04%)Summary
- As of today (June 28, 2025), DNLI quarterly cash flow from operations is -$131.47 million, with the most recent change of -$47.75 million (-57.04%) on March 31, 2025.
- Over the past year, DNLI quarterly CFO has dropped by -$17.85 million (-15.71%).
- DNLI quarterly CFO is now -125.58% below its all-time high of $513.91 million, reached on December 31, 2020.
Performance
DNLI quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFO:
-$365.54M-$17.85M(-5.13%)Summary
- As of today (June 28, 2025), DNLI TTM cash flow from operations is -$365.54 million, with the most recent change of -$17.85 million (-5.13%) on March 31, 2025.
- Over the past year, DNLI TTM CFO has increased by +$47.27 million (+11.45%).
- DNLI TTM CFO is now -186.95% below its all-time high of $420.40 million, reached on March 31, 2021.
Performance
DNLI TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
DNLI Cash from operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2.9% | -15.7% | +11.4% |
| 3 y3 years | -64.5% | -82.3% | -56.7% |
| 5 y5 years | -129.4% | -141.3% | -108.0% |
DNLI Cash from operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -64.5% | +2.9% | -206.5% | at low | -64.7% | +11.4% |
| 5 y | 5-year | -183.6% | +2.9% | -125.6% | at low | -186.9% | +11.4% |
| alltime | all time | -183.6% | +2.9% | -125.6% | at low | -186.9% | +11.4% |
DNLI Cash from operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$131.47M(+57.0%) | -$365.54M(+5.1%) |
| Dec 2024 | -$347.69M(-2.9%) | -$83.72M(+41.6%) | -$347.69M(-4.1%) |
| Sep 2024 | - | -$59.14M(-35.2%) | -$362.64M(-7.2%) |
| Jun 2024 | - | -$91.22M(-19.7%) | -$390.86M(-5.3%) |
| Mar 2024 | - | -$113.62M(+15.2%) | -$412.81M(+15.3%) |
| Dec 2023 | -$357.99M(+46.3%) | -$98.66M(+12.9%) | -$357.99M(+7.8%) |
| Sep 2023 | - | -$87.36M(-22.8%) | -$332.00M(+10.0%) |
| Jun 2023 | - | -$113.17M(+92.5%) | -$301.68M(+30.4%) |
| Mar 2023 | - | -$58.80M(-19.1%) | -$231.41M(-5.4%) |
| Dec 2022 | -$244.72M(+15.8%) | -$72.66M(+27.4%) | -$244.72M(+3.0%) |
| Sep 2022 | - | -$57.05M(+33.0%) | -$237.55M(+7.0%) |
| Jun 2022 | - | -$42.90M(-40.5%) | -$221.94M(-4.9%) |
| Mar 2022 | - | -$72.11M(+10.1%) | -$233.26M(+10.3%) |
| Dec 2021 | -$211.39M(-150.8%) | -$65.49M(+58.1%) | -$211.39M(-157.4%) |
| Sep 2021 | - | -$41.43M(-23.6%) | $368.02M(-10.1%) |
| Jun 2021 | - | -$54.22M(+7.9%) | $409.54M(-2.6%) |
| Mar 2021 | - | -$50.24M(-109.8%) | $420.40M(+1.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | $416.15M(-374.6%) | $513.91M(>+9900.0%) | $416.15M(-386.2%) |
| Sep 2020 | - | $86.00K(-100.2%) | -$145.41M(-17.3%) |
| Jun 2020 | - | -$43.36M(-20.4%) | -$175.93M(+0.1%) |
| Mar 2020 | - | -$54.49M(+14.4%) | -$175.75M(+15.9%) |
| Dec 2019 | -$151.58M(-402.5%) | -$47.64M(+56.5%) | -$151.58M(+1310.3%) |
| Sep 2019 | - | -$30.43M(-29.5%) | -$10.75M(-29.0%) |
| Jun 2019 | - | -$43.17M(+42.4%) | -$15.13M(+9.8%) |
| Mar 2019 | - | -$30.32M(-132.5%) | -$13.78M(-127.5%) |
| Dec 2018 | $50.12M(-165.4%) | $93.19M(-367.6%) | $50.12M(-181.6%) |
| Sep 2018 | - | -$34.82M(-16.7%) | -$61.41M(+26.6%) |
| Jun 2018 | - | -$41.82M(-224.6%) | -$48.50M(+100.0%) |
| Mar 2018 | - | $33.58M(-283.1%) | -$24.25M(-68.4%) |
| Dec 2017 | -$76.64M(+6.6%) | -$18.34M(-16.4%) | -$76.64M(+31.5%) |
| Sep 2017 | - | -$21.92M(+24.8%) | -$58.30M(+60.3%) |
| Jun 2017 | - | -$17.57M(-6.6%) | -$36.38M(+93.4%) |
| Mar 2017 | - | -$18.81M | -$18.81M |
| Dec 2016 | -$71.91M(+377.7%) | - | - |
| Dec 2015 | -$15.05M | - | - |
FAQ
- What is Denali Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Denali Therapeutics?
- What is Denali Therapeutics annual CFO year-on-year change?
- What is Denali Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Denali Therapeutics?
- What is Denali Therapeutics quarterly CFO year-on-year change?
- What is Denali Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Denali Therapeutics?
- What is Denali Therapeutics TTM CFO year-on-year change?
What is Denali Therapeutics annual cash flow from operations?
The current annual CFO of DNLI is -$347.69M
What is the all time high annual CFO for Denali Therapeutics?
Denali Therapeutics all-time high annual cash flow from operations is $416.15M
What is Denali Therapeutics annual CFO year-on-year change?
Over the past year, DNLI annual cash flow from operations has changed by +$10.30M (+2.88%)
What is Denali Therapeutics quarterly cash flow from operations?
The current quarterly CFO of DNLI is -$131.47M
What is the all time high quarterly CFO for Denali Therapeutics?
Denali Therapeutics all-time high quarterly cash flow from operations is $513.91M
What is Denali Therapeutics quarterly CFO year-on-year change?
Over the past year, DNLI quarterly cash flow from operations has changed by -$17.85M (-15.71%)
What is Denali Therapeutics TTM cash flow from operations?
The current TTM CFO of DNLI is -$365.54M
What is the all time high TTM CFO for Denali Therapeutics?
Denali Therapeutics all-time high TTM cash flow from operations is $420.40M
What is Denali Therapeutics TTM CFO year-on-year change?
Over the past year, DNLI TTM cash flow from operations has changed by +$47.27M (+11.45%)